Financial aspects of lung cancer

Tumors of the Chest: Biology, Diagnosis and Management

Volumn , Issue , 2006, Pages 649-659

  Russell Hoverman, J ^a  

^a Texas Oncology PA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84892792668     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/3-540-31040-1_56     Document Type: Chapter

References (115)

1. Murray CJL. Rethinking DALYs. In: Murray CJL, Lopez AD (eds) Global Burden of Disease Study 1996. Boston: Harvard School Public Health, 1996:1.
2. Murray CJL, Lopez AD. Global mortality, disability and the contribution of risk factors. Global Burden of Disease Study. Lancet 1997;349:1436.
3. Murray CJL, Lopez AD. Alternative visions of the future: projecting mortality and disability, 1990-2020. In: Murray CJL, Lopez AD (eds) Global Burden of Disease Study 1996. Boston: Harvard School Public Health, 1996:361.
4. Mackay J, Eriksen M. The Tobacco Atlas. Brighton, UK: Myriad Edition, 2002.
5. Rang HY, Kim HJ, Park TK, Jee SH, Nam CM, Park HW. Economic burden of smoking in Korea. Tob Control 2003;12:37.
6. Sansom C. Provisions of cancer care in Eastern Europe. Lancet Oncol 2002;3:203.
7. Brown ML, Lipscomb J, Snyder C. The burden of illness of cancer: economic cost and quality of life. Annu Rev Public Health 2001;22:91.
8. Goodwin PJ, Shepherd FA. Economic issues in lung cancer: a review. JClin Oncol 1998;16:3900.
9. Bosanquet N, Sikora K. The economics of cancer in the UK. Lancet Oncol 2004;5:568.
10. NHMRC. National Health and Medical Research Council Clinical Practice Guidelines for the prevention, diagnosis and management of lung cancer, http://www.nhmrc.gov.au/publications/-files/cp97.pdf. (Accessed 9/3/05)
11. Earle CC, Evans WK. Management issues for stage IV non-small-cell lung cancer. Cancer Control 1997;4:307.
12. Hillner BE, McDonald MK, Desch CE, et al. Costs of care associated with non-small cell lung cancer in a commercially insured cohort. J Clin Oncol 1998;16:1420.
13. Riley GF, Potosky AL, Lubitz JD, Kessler LG. Medicare payments from diagnosis to death for elderly cancer patients by stage at diagnosis. Med Care 1995;33:828.
14. Chouaid C, Molinier L, Combescure C, et al. Economics of the clinical management of lung cancer in France: an analysis using a Markov model. Br J Cancer 2004;90:397.
15. McCarthy EP, Phillips RS, Zhong Z, et al. Dying with cancer: patients function, symptoms and case references as death approaches. J Am Geriatr Soc 2000;48:S110.
16. Himmelstein DU, Warren E, Thorne D, Woolhandler S. Market watch: illness and injury as contributors to bankruptcy. http://www.healthaffairs.org/cgi/ content/full/hlthaff.w5.63/DCI. (Accessed 9/3/05).
17. Arozullah AM, Calhoun EA, Wolf M, et al. The financial burden of cancer: estimates from a study of insured women with breast cancer. J Support Oncol 2004;2:271.
18. Early Breast Cancer Trialists Collaborative Group. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28, 896 women. N Engl J Med 1988;319:1681.
19. Peto R, Collins R, Gray R. Large-scale randomized evidence: large simple trials and overviews of trials. J Clin Epidemiol 1995;48:23.
20. Piedbois P, Buyse M. Meta-analyses based on abstracted data: a step in the right direction, but only a first step. J Clin Oncol 2004;22:3839.
21. Le Lorier J, Gregoire G, Benhaddad A, et al. Discrepancies between meta-analyses and subsequent large, randomized, controlled trials. N Engl J Med 1997;337:536.
22. Ioannidis JP, Cappelleri JC, Lau J. Issues in comparisons between meta-analyses and large trials. JAMA 1998;279:1089.
23. Der Simonian R, Levine R. Resolving discrepancies between a meta-analyses and a subsequent large controlled trial. JAMA 1999;282:664.
24. Altman DG, Schulz KF, Moher D, et al. The revised CON-SORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med 2001;134:663.
25. Evidence-Based Medicine Working Group. Evidence-based medicine. JAMA 1992;2668:2420.
26. Slavin RE. Best evidence synthesis: an intelligent alternative to meta-analyses. J Clin Epidemiol 1995;48:9.
27. Jadad AR, Cook DJ, Jones A, et al. Methodology and reports of systematic review and meta-analyses. JAMA 1998;280:278.
28. American Society of Clinical Oncology. American Society of Clinical Oncology recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. J Clin Oncol 1994;12:2471.
29. Winn R, McClure J. The NCCN clinical practice guidelines in oncology: a primer for users. J Natl Cancer Center Network 2003;1:5.
30. Hayman JA, Weeks JC. Techniques used in the assessment of cost-effectiveness. Dis Breast Updates 1999;3:1.
31. Earle CC, Coyle D, Evans WK. Cost-effective analysis in oncology. Ann Oncol 1998;9:475.
32. Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC. Panel on cost-effectiveness analysis in health and medicine. JAMA 1996;276:1172.
33. Fisher ES, Wennberg DE, Stukel TA, et al. The implications of regional variations in Medicare spending. Part 1: the content, quality and accessibility of care. Ann Intern Med 2003;138:279.
34. Wennberg JE. Unwarranted variations in healthcare delivery: implications for academic medical centers. BMJ 2002;325:961.
35. Hoverman JR, Robertson SM. Lung cancer: a cost and outcomes study based on physician practice patterns. Disease Management 2004;7:112.
36. Gelijns AL, Brown LD, Magnell C, et al. Evidence, politics and technological change. Health Affairs 2005;24:29.
37. Anthonisen NR, Skeans MA, Wise RA, et al. The Lun Health Study Research Group. The effects of a smoking cessation intervention on 14.5-year mortality. Ann Intern Med 2005;142:233.
38. Kelley MJ, McCrory DC. Prevention of lung cancer: summary of published evidence. Chest 2003;123:50S.
39. Hopkins DP, Briss PA, Ricard CJ. Reviews of evidence regarding interventions to reduce tobacco use and exposure to environmental tobacco smoke. Am J Prev Med 2001;20:16.
40. Munafo M. Pharmacological therapy is relatively cost-effective when added to counseling. Evidence-based Healthcare 2003;7:44.
41. Karnath B. Smoking cessation. Am J Med 2002;112:399.
42. Koike T, Terashima M, Takizawa T, et al. The influence of lung cancer mass screening on surgical results. Lung Cancer 1999;24:74.
43. Humphrey LL, Teutsch S, Johnson M. Lung cancer screening with sputum cytologic examination, chest radiography and computed tomography: An update for the US Preventative Services Task Force. Ann Intern Med 2004;140:740.
44. Mahadevia PJ, Fleisher LA, Frick KD, et al. Lung cancer screening with helical computed tomography in older adult smokers: a decision and cost-effectiveness analysis. JAMA 2003;289:313.
45. Gohagan J, Marcus P, Fagerstrom R, et al. Baseline findings of a randomized feasibility trial of lung cancer screening with spiral CT scan vs chest radiograph: The Lung Screening Study of the National Cancer Institute. Chest 2004;126:114.
46. Pastorino U, Bellomi M, Landoni C, et al. Early lung-cancer detection with spiral CT and positron emission tomography in heavy smokers: 2-year results. Lancet 2003;362:593.
47. Chirikos TN, Hazelton T, Tockman M, Clark R. Screening for lung cancer with CT: a preliminary cost-effectiveness analysis. Chest 2002;121; 1507.
48. Herder GJM, Verboom P, Smit EF, et al. Practice, efficacy and cost of staging suspected non-small cell lung cancer: a retrospective study in two Dutch hospitals. Thorax 2002;57:11.
49. Gambhir SS, Shepherd JE, Shah BD, et al. Analytical decision model for the cost-effective management of solitary pulmonary nodules. J Clin Oncol 1998;16:2113.
50. Dietlein M, Weber K, Gandjour A, et al. Cost-effectiveness of FDG-PET for the management of solitary pulmonary nodules: a decision analysis based on cost reimbursement in Germany. Eur J Nucl Med 2000;27:1441.
51. Sloka JS, Hollett JD, Mathews M. Cost-effectiveness of positron emission tomography for non-small lung carcinoma in Canada. Med Sci Monit 2004;10:MT73.
52. Kalff V, Hicks RI, MacManus MP, et al. The clinical impact of F-18 FDG positron emission tomography (PET) in patients with non-small cell lung cancer: a prospective study. J Clin Oncol 2001;19:111.
53. MacManus MP, Wong K, Hicks RJ, et al. Early mortality after radical radiotherapy for non-small cell lung cancer: comparison of PET-staged and conventionally staged cohorts treated at a large tertiary referral center. Int J Radiat Oncol Biol Phys 2002;52:351.
54. Hoekstra CH, Stroobants SG, Hoekstra OS, et al. The value of (18F) fluoro-2-deoxy-D-glucose positron emission tomography in the selection of patients with IIIA-N2 nonsmall cell lung cancer for combined modality treatment. Lung Cancer 2003;39:151.
55. MacManus MP, Hicks RJ, Ball DL, et al. F-18 fluorodeoxyglucose positron emission tomography staging in radical radiotherapy candidates with non-small cell lung carcinoma: powerful correlation with survival and high impact on treatment. Cancer 2001;92; 886.
56. Viney RC, Boyer MJ, King MT, et al. Randomized controlled trial of the role of positron emission tomography in the management of stage I and II non-small cell lung cancer. J Clin Oncol 2004;22:2357.
57. Esnaola NF, Lazarides SN, Mentzer SJ, Kuntz KM. Outcomes and cost-effectiveness of alternative staging strategies for non-small-cell lung cancer. J Clin Oncol 2001;20:263.
58. Kelly RF, Tran T, Holmstrom A, Murar J, Segurola RJ. Accuracy and cost-effectiveness of [18F]-2-fluoro-deoxy-D-glucose-positron emission tomography scan in potentially resectable non-small cell lung cancer. Chest 2004;125:1413.
59. Harewood GC, Wiersema MJ, Edell EX, Liebow M. Costminimization analysis of alternative diagnostic approaches in a modeled patient with non-small cell lung cancer and subcarinal lymphadenopathy. Mayo Clin Proc 2002;77:155.
60. Detterbeck FC, Falen S, Rivera MP, Halle JS, Socinski MA. Seeking a home for a PET, part 2: defining the appropriate place for positron emission tomography imaging in the staging of patients with suspected lung cancer. Chest 2004;125:2300.
61. Toloza EM, Harpole L, McCrory DC. Noninvasive staging of non-small lung cancer: a review of the current evidence. Chest 2002;123:137S.
62. Vansteenkiste J, Fischer BW, Dooms C, Mortensen J. Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review. Lancet Oncol 2004;5:531.
63. Colice GL, Rubins J, Unger M, American College of Chest Physicians. Follow-up and surveillance of the lung cancer patient following curative-intent therapy. Chest 2003;123:272S.
64. Egermann U, Jaeggi K, Habicht JM, Perruchoud AP, Dalquen P, Soler M. Regular follow-up after curative resection of non-small cell lung cancer: a real benefit for patients? Eur Respir J 2002;19:464.
65. Evans WK, Will BP, Berthelot JM, Wolfson MC. Estimating the cost of lung cancer diagnosis and treatment in Canada: the POHEM model. Can J Oncol 1995;4:408.
66. Ramsey SD, Howlader N, Etzioni RD, Donato B. Chemotherapy use, outcomes, and costs for older persons with advanced non-small-lung cancer: evidence from surveillance, epidemiology and end results-Medicare. J Clin Oncol 2004;22:4971.
67. Ramsey SD, Moinpour CM, Lovato LC, et al. Economic analysis of vinorelbine plus cisplatin versus paclitaxel plus carboplatin for advanced non-small-cell lung cancer. J Natl Cancer Inst 2002;94:291.
68. ELVIS Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small lung cancer. J Natl Cancer Inst 1999;91:66.
69. Rapp E, Pater VL, Willan A, et al. Chemotherapy can prolong survival in patients with advanced non-small cell lung cancer: report of a Canadian multicenter randomized trial. J Clin Oncol 1998;16:633.
70. Non Small Cell lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 1995;311:899.
71. Dest CE, Hillner BE, Smith TJ. Economic considerations in the care of lung cancer patients. Curr Opin Oncol 1996;8:126.
72. Berthelot JM, Will BP, Evans WK, Coyle D, Earle CC, Bordeleau L. Decision framework for chemotherapy interventions for metastatic non-small-cell lung cancer. J Natl Cancer Inst 2000;92:1321.
73. Evans WK, Will BP, Bertholet J, Earle CC. Cost of combined modality interventions for stage III non-small-cell lung cancer. J Clin Oncol 1997;15:3030.
74. Schiller JH, Harrington D, Sandler A, et al. A randomized phase III trial of four chemotherapy regimens in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2000;19:1a.
75. Rubio-Terres C, Tisaire JL, Kobina S, Moyano A. Costminimization analysis of three regimens of chemotherapy (docetaxel-cisplatin, paclitaxel-cisplatin, paclitaxel-carboplatin) for advanced non-small-cell lung cancer. Lung Cancer 2002;35:81.
76. Johnson DH, Adak S, Cella DF, et al. Topotecan vs observation following cisplatin plus etoposide in extensive stage small cell lung cancer (E7593): a phase III trial of the Eastern Cooperative Group. Proc Am Soc Clin Oncol 2000;19:482a.
77. Bleehan NM, Girling DJ, Mackin D, et al. A randomized trial of three vs six courses of etoposide, cyclophosphamide, methotrexate and vincristine or 6 courses of etoposide and ifosfamide in small cell lung cancer (SCLC). I. Survival and prognostic factors. Medical Research Council Lung Cancer Working Party. Br J Cancer 1993;8:1150.
78. Beith JM, Clarke SJ, Woods RL, et al. Long-term follow-up of a randomized trial of combined chemoradiotherapy induction treatment, with and without maintenance chemotherapy in patients with small cell carcinoma of the lung. Eur J Cancer 1996;32 a: 438.
79. Buccheri GF, Ferrigno D, Curcio A, et al. Continuation of chemotherapy versus supportive care alone in patients with inoperable non-small cell lung cancer and stable disease after two or three cycles of MACC. Cancer 1989;63:428.
80. Smith IE, O'Brien MER, Talbot DC, et al. Duration of chemotherapy for advanced non-small cell lung cancer (NSCLC): a phase III randomized trial of three vs six courses of mitomycin C, vinblastine, cisplatin (MVP). J Clin Oncol 2001;19:1336.
81. Socinski MA, Schell MJ, Peterman A, et al. A phase III trial comparing a defined duration of therapy vs continuous therapy followed by second-line therapy in advanced stage IIIB/IV non-small cell lung cancer. J Clin Oncol 2002;20:1335
82. Sheperd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel vs best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095.
83. Foscell FV, De Vore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum containing chemotherapy regimens. J Clin Oncol 2000;18:2354.
84. von Pawel J, Schiller JH, Sheperd FA, et al. Topotecan vs cyclophosphamide, doxorubicin and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999;17:658.
85. Huisman C, Smit EF, Postmus PE. Second-line chemotherapy in relapsing or refractory non-small-cell lung cancer: a review. J Clin Oncol 2000;18:3722.
86. Holmes J, Dunlop D, Hemmett L, Sharplin P, Bose U. A cost-effectiveness analysis of docetaxel in the second-line treatment of non-small cell lung cancer. Pharmacoeconomics 2004;22:581.
87. Massarelh E, Andre F, Liu DD, et al. A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including a platin and docetaxel for recurrent non-small-cell lung cancer (abstract 1323). Proc Am Soc Clin Oncol 2002;21:331a.
88. Delbaldo C, Michiels S, Syz N, et al. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. JAMA 2004;292:470.
89. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed vs docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589.
90. Kelly K, Crowley J, Bunn PA, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced nonsmall-cell lung cancer: A Southwest Oncology Group trial. J Clin Oncol 2001;19:3210.
91. Gandara DR, Crowley J, Livingston RB, et al. Evaluation of cisplatin intensity in metastatic non-small cell lung cancer: a phase II study of the Southwest Oncology group. J Clin Oncol 1993;11:873.
92. Cole JT, Gralla RJ, Rittenberg CN, et al. Defining the dose of docetaxel in combination chemotherapy of non-small cell lung cancer: preserving efficacy with lower dose regimens (abstract 1671). Proc Am Soc Clin Oncol 1997;16:465a.
93. Costich TD, Lee FC. Improving cancer care in a Kentucky managed care plan: a case study of cancer disease management. Disease Management 2003;6:9.
94. Seidenfeld J, Piper M, Flamm C, et al. Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials. J Natl Cancer Inst 2001;93:1204.
95. Rizzo DH, Lichtin AE, Woolf SH, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 2002;19:4083.
96. Browman GP. Standards of proof, standards of practice, and proof of standards: a tale of two trials. J Clin Oncol 2005;23:2583.
97. Witzig TE, Silberstein TP, Loprinzi CL, et al. Phase III, randomized, double-blind study of epoetin alfa vs placebo in anemic patients with cancer undergoing chemotherapy. J Clin Oncol 2004;23; 2606.
98. Adams JR, Lyman GH, Djubegovic B, Feinglass J, Bennett CL. G-CSF as prophylaxis of febrile neutropenia in SCLC. Expert Opin Pharmacother 2002;3:1273.
99. Bunn PA Jr, Crowley J, Kelly K, et al. Chemotherapy with or without granulocyte-macrophage colony stimulating factors in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group. J Clin Oncol 1995;13:1632.
100. Hartmann LC, Tschetter LK, Habermann TM, et al. Granulocyte colony stimulating factors in severe chemotherapy-induced afebrile neutropenia. N Engl J Med 1997;336:1776.
101. Delaney G, Barton M, Jacob S, Jalaludin B. A model for decision making for the use of radiotherapy in lung cancer. Lancet Oncol 2003;4:120.
102. Tyldesley S, Boyd C, Schulze K, et al. Estimating the need for radiotherapy for lung cancer: an evidence-based epidemiologic approach. Int J Radiat Oncol Biol Phys 2001;49:973.
103. Barbera L, Walker H, Foroudi F, et al. Estimating the benefit and cost of radiotherapy for lung cancer. Int J Technol Assess Health Care 2004;20:545.
104. McQuay HJ, Carroll D, Moore RA. Radiotherapy for painful bone metastases: a systematic review. Clin Oncol 1997;9:150.
105. Moran JM, Elshaikh MA, Lawrence TS. Radiotherapy: what can be achieved by technical improvements in dose delivery? Lancet Oncol 2005;6:51.
106. Martel MK. Advanced radiation treatment planning and delivery approaches for treatment of lung cancer. Hematol Oncol Clin North Am 2004;18:231.
107. van Tinteren H, Hoekstra OS, Smit EF, et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomized trial. Lancet 2002;359:1388.
108. Pasic A, Brokx HA, Noordegraaf AV, Paul RM, Postmus PE, Sutedja TG. Cost-effectiveness of early intervention: comparison between intraluminal bronchoscopic treatment and surgical resection for T1N0 lung cancer patients. Respiration 2004;71:391.
109. Van Schil P. Cost analysis of video-assisted thoracic surgery vs thoracotomy: critical review. Eur Respir J 2003;22:735.
110. Braud A, Levy-Piedbois C, Piedbois P, et al. Direct treatment costs for patients with lung cancer from first recurrence to death in France. Pharmacoeconomics 2003;21:671.
111. Campbell DE, Lynn J, Louis TA, Shugarman LR. Medicare program expenditures associated with hospice use. Ann Intern Med 2004;140:269.
112. SUPPORT Principal Investigators. A controlled trial to improve care for seriously ill hospitalized patients. JAMA 1995;274:1591.
113. Beresford L, Byock I, Twohig J. Promoting excellence: financial implications of promoting excellence in end-of-life care, http://www. promotingexcellence.org/finance/ (Accessed 3/1/2005).
114. Ripamonti C, Bianchi M. The use of methadone for cancer pain. Hematol Oncol Clin North Am 2002;16:543.
115. Earle CC, Chapman, RH, Baker CS, et al. Systematic overview of cost-utility assessments in oncology. J Clin Oncol 2000;18:3302.